Bone Graft Substitutes Market 2020 – Investment Strategy, Outlook and Key Development till 2027

Global Bone Graft Substitutes Market to Witness a Surge in Demand during the Forecast Period

Market Research Future (MRFR)’s latest study reveals that the global bone graft substitutes market is expected to expand at 6.52% CAGR during the forecast period 2017 to 2027. The Bone Graft Substitutes Market Size is set to reach a valuation of USD 5,031 Mn by the end of the assessment period. The increasing prevalence of diseases related to bones has intensified the demand for bone graft substitutes. Additionally, the rising awareness about the developments in bone graft substitutes coupled with rising healthcare expenditure is likely to augment the market size and revenue over the next couple of years.

The painful procedure related to autografts have paved the way for developments in the bone graft substitutes market. Hence, the demand for alternatives such as allografts, xenografts, and synthetic bone grafts has been on the rise. It is projected to aid the proliferation of the market in the forthcoming years by accelerating its adoption.

The growth of the bone graft substitutes market is guided by the factors such as increasing orthopedic problems, exponential geriatric population, and rising demand for reconstructive orthopedic treatments. The adoption of bone graft substitutes in the oral healthcare sector is another factor responsible for catalyzing the growth of the bone graft substitutes market through the assessment period.

The bone graft substitutes market is poised to remain highly lucrative in the foreseeable future. However, risks associated with disease transmission in allografts and xenograft as well as graft rejection, improper fixation, etc. are prognosticated to restrict the market expansion over the forecast period.

Competitive Dashboard:

Sone of the key players profiled in the report includes ACE Surgical Supply Company, Inc., Dentium Co., Ltd., BioHorizons IPH, Inc., Dentsply Sirona, Medtronic plc, Stryker Corporation, Zimmer Biomet, and Institut Straumann AG.

Market Segmentation:

By type, the global bone graft substitutes market is segmented into autograft, demineralized bone matrix, synthetic bone grafts, bone morphogenetic protein, and others.

By application, the bone graft substitutes market has been segmented into spinal fusion, joint reconstruction, long bone, dental, foot & ankle, and others.

Browse More Information:- 

Regional Insights:

By region, the global bone graft substitutes market has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas accounted for the largest share of the global market in 2016. It is expected to retain a significant share of the market by the end of 2027 striking a CAGR of 6.1%. The growth is attributable to the technological advancements in health care, the presence of key players, etc. The developed healthcare sector of the U.S. is poised to be one of the primary revenue generators in the regional bone graft substitutes market.

Europe is the second largest market for bone graft substitutes. It is estimated to thrive at 6.76% CAGR owing to increasing awareness about bone graft substitutes and rising healthcare expenditure. Meanwhile, Asia Pacific is set to register a relatively higher CAGR of 6.85% during the forecast period. The presence of fast-developing economies such as China and India are immensely supporting the growth of the bone graft substitutes market in the region. The trend is likely to perpetuate over the next couple of years.

The Middle East & Africa is expected to exhibit steady growth due to the developments in the healthcare sector in Gulf nations. However, the poor socio-economic situation in African regions remains an impediment to the market growth.

Saliva Collection and Diagnostic Market 2020 Global Trend, Segmentation and Opportunities, Forecast 2025

Approval of Salivary Disease Biomarkers Driving the Saliva Collection Devices & Diagnostic Market

The global Saliva Collection and Diagnostic Market Size is presumed to demonstrate 10% CAGR during the forecast period (2017-2022). As per a new report by Market Research Future (MRFR), the demand for saliva collection devices and diagnostics is increasing significantly as saliva is considered as an optimal transitional research tool. An ideal diagnostic medium and transitional research tool, saliva is used as a part of novel approaches in order to provide molecular biomarkers a variety of systemic and oral infections. Saliva tests are performed to detect periodontitis, caries risk, oral cancer, breast cancer, systemic disorders like HIV, hepatitis, and HCV, and salivary gland diseases.

The diagnostic testing has experienced tremendous growth in the last few years, with painful and expensive blood draws being replaced by saliva and other means. Saliva acts as an important means in the diagnostic of several types of diseases. The application of saliva collection devices to detect periodontitis, breast cancer, oral cancer, salivary gland diseases, hepatitis, HIV, and HCV is considered to fuel the market growth during the appraisal period. Approval of salivary disease biomarkers is also presumed to be a key factor stimulating the market growth to a great extent. With the rising prevalence of several diseases along with the growing number of general practice clinics, the market for saliva is considered to flourish during the estimated period. Moreover, high investment by the market giants in research and development activities to launch new products is further propelling the market growth.

On the flip side, lack of awareness regarding saliva collection is considered to slowdown the market growth for saliva collection devices and diagnosis during the assessment period. Additionally, availability of more advanced diseases used to collect saliva are likely to deter the market growth in the coming years.

Competitive Dashboard

The prominent players operating the global saliva collection devices & diagnostic market are Neogen Corporation, Alere, AboGen Inc., Oasis Diagnostics Corporation, OraSure Technologies Inc., Quest Diagnostics, and others.

Segmental Analysis

The global saliva collection devices & diagnostic market has been segmented on the basis of site of collection, application, and end-users.

By mode of site of collection, the global saliva collection devices & diagnostic market has been segmented into sublingual/submandibular gland collection devices, parotid gland collection devices, minor salivary glands collection devices, and others.

By mode of application, the global saliva collection devices & diagnostic market has been segmented into pharmaceutical, biotechnology, forensics, and others. Among these, the biotechnology segment is predicted to occupy the largest market share and is expected to maintain its dominance in the coming years. the growth is credited to the rising use of collection devices in this field.

By mode of end-users, the global saliva collection devices & diagnostic market has been segmented into general practice, dentistry, laboratories, and others. Among these, the laboratories segment is likely to occupy the largest market share and is presumed to flourish at a lucrative rate owing to the rising use of saliva collection tubes in the laboratories.

Browse More Information:- 

Regional Insights

Geographically, the saliva collection devices & diagnostic market span across regions namely, North America, Europe, Middle East & Africa, and Asia Pacific.

Among all the regions, North America is anticipated to occupy the major market share and expand at a CAGR of 10.7% during the anticipated period. the growth is credited to the increasing prevalence of diabetic patients in this region.

The European region is considered to occupy the second-largest position with a CAGR of 10.9 %. Germany is predicted to command the overall market in this region with a market share of 26.3 %. The market was valued at USD 920.2 million in 2015 and is presumed to garner USD 1,923.0 million by the end of 2022.

Human Growth Hormone Market Drivers, Segmentations, Key Players, Analysis & Forecast 2020 – 2023

Human Growth Hormone Market to Exhibit Robust Growth

Human Growth Hormone Market Size is predicted to expand at an impressive 7.50% CAGR over the forecast period (2018-2023). Growth hormone (GH) popularly known as somatotropin or human growth hormone (HGH) is a peptide hormone which stimulates growth, cell regeneration and cell reproduction in humans as well as animals. Thus, it is crucial in human development. Major functions of such hormones include boost DE iodination of T4-T3, stimulate the immune system, cutdown uptake of glucose, stimulates growth of internal organs except the brain, increases protein synthesis, plays a pivotal part in homeostasis, promotes lipolysis, increase muscle mass, strengthen and increase mineralization of bones, increase calcium retention and increase height during childhood.

There are plentiful factors that is boosting the growth of the human growth hormone market. These factors as per the Market Research Future (MRFR) report include increasing incidences of serious chronic diseases, technological developments, creation of top-quality healthcare solutions, increased healthcare expenditure, burgeoning need for human growth hormone medicines, growing occurrence of deficiency diseases related to human growth hormone, and advancements namely recombinant DNA technology used for making growth hormone drugs. Besides, many key players are investing greatly and also collaborating for the R&D of growth hormone drugs that is driving the market growth. On the contrary, lack of awareness, strict regulatory approvals, adverse effects related with the use of synthetic growth hormones and low penetration of latest healthcare solutions are factors that may deter the human growth hormone market growth over the forecast period.

Human Growth Hormone Market Top Leaders Share Overview

Leading players profiled in the human growth hormone market include Lifetech Labs, Ipsen S.A., Merck KGaA, Zhongshan Hygene Biopharm Co. Ltd., Biopartners GmbH, Novartis AG, Genetech Inc., GeneScience Pharmaceuticals Co. Ltd., Eli Lilly and Company, Anhui Anke Biotechnology Co. Ltd., Novo Nordisk A/S, and Pfizer Inc.

Market Segmentation

MRFR report provides an extensive segmental analysis of the human growth hormone market on the basis of route of administration, brand, distribution channel and application.

Based on brand, it is segmented into omnitrope, sainzen, mumatrope, genotropin, norditropin and others. Of these, norditropin will have the maximum share in the market over the forecast period.

Based on application, the human growth hormone market is segmented into prader-willi syndrome, turner syndrome, small for gestational age, idiopathic short stature, growth hormone deficiency and others. Of these, growth hormone deficiency will lead the market over the forecast period.

Browse More Information:- 

Based on route of administration, it is segmented into oral, intravenous, intramuscular and subcutaneous. Of these, subcutaneous will dominate the market over the forecast period.

Based on distribution channel, the human growth hormone market is segmented into e-commerce websites, retail pharmacies, clinics and hospital pharmacies. Of these, hospital pharmacies will have maximum share in the market over the forecast period.

Regional Analysis

By region, the human growth hormone market covers growth opportunities and latest trends across Americas, Asia Pacific, Europe and Middle East and Africa. Of these, Americas will garner highest share in the market owing to widespread awareness about human growth hormone amid consumers, high healthcare spending and increasing incidence of human growth hormone deficiency. The human growth hormone market in the European region will have the second major share followed by Asia Pacific. Sales of such hormones in GCC countries too have picked up pace that brings the Middle East and Africa under the radar of market experts operating on the global level.

Myelodysplastic Syndrome (MDS) Drugs Market 2020 Insights Business Opportunities, Current Trends and Restraints Forecast 2025

The Global Myelodysplastic Syndrome (MDS) Drugs Market is expected to grow significantly over the forecast period. The Myelodysplastic Syndrome (MDS) Drugs market held a valuation of USD 1,581.59 million in 2018 and is projected to register a CAGR of 10.1% over the forecast period.

The increasing participation of key players is one of the key factors driving the Myelodysplastic Syndrome (MDS) drugs market. In 2018, the US Food and Drug Administration approved generic injectable product decitabine for Lupin Ltd. There are various other MDS medications available in the market.

Various other factors that are driving the MDS drugs market are the promotion of clinical studies related to MDS, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drugs manufactures.

However, the risk of infections during blood transfusions and side-effects of chemotherapy may hamper market growth over the forecast period.

Key Players for Global Myelodysplastic Syndrome (MDS) Drugs Market

  • BluePoint Laboratories
  • Celgene Corporation
  • Celgene Europe Limited
  • Reddy’s Laboratories, Inc.
  • Johnson & Johnson
  • Lupin Ltd Corporation
  • Otsuka America Pharmaceutical Inc.
  • Sandoz
  • Shilpa Medicare Limited
  • Sun Pharmaceutical Industries Inc.

Segments for Global Myelodysplastic Syndrome (MDS) Drugs Market

The global Myelodysplastic Syndrome (MDS) drugs market is segmented based on product, type of syndrome, route of administration, end user, and region.

Based on product, the global Myelodysplastic Syndrome (MDS) drugs market is further segmented into chemotherapy, immunomodulatory drugs, and others. The chemotherapy segment is sub-segmented as conventional drugs and hypomethylating drugs. Hypomethylating drugs include Azacitidine and Decitabine. Conventional drugs comprise Cytarabine, Daunorubicin, and Idarubicin.

The MDS drugs market at a global level is segmented on type of syndrome into refractory cytopenia with multilineage dysplasia, refractory anemia, refractory anemia with excess blasts, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and others.

Based on the route of administration, the market is segmented into oral, parenteral, and others. The MDS drugs available in the market are administered through parenteral route, for instance, intravenous or subcutaneous. The parental route has a quick effective after administration. Thus, the parenteral segments have greater growth compared to the other dosage forms in this segment. Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. MDS patients are treated in the hospitals, clinics, and ambulatory surgical centers. MDS drugs are prescribed by physicians to patients, as in critical conditions, it could lead to blood cancer. The hospitals segment holds the major share in this segment as it deals with a larger number of MDS patients compared to clinics and ambulatory surgical centers.

Browse More Information:- 

Regional Analysis for Global Myelodysplastic Syndrome (MDS) Drugs Market

In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The global MDS drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European global MDS drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The MDS drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The global Myelodysplastic Syndrome drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.

Dental Software Market By Key Vendors, Regions, Trends with Industry Study & Forecast to 2027

Market Analysis

The global dental software market is anticipated to grow phenomenally at a staggering 8% CAGR during the predicted years (2016-2027). The field of dentistry has developed at an extensive pace and also witnessing a rising influx of technological advancements such as dental software. This concept has made the job of a dentist simpler and has also increased the efficiency. Dental software is available in different forms including free dental software, open dental software, offline dental software amid others. The latest dental software comes with the facility to appoint schedules, period charting, reminder services, payment, tooth charting and electronic health records that has turned into a boon for dentists owing to its ability of extensively streamlining the process. Such software is in great demand owing to its flexibility, reliability and practicality.

There are myriad opportunities and factors that is assisting in the growth of the global dental software market as per Market Research Future (MRFR) report. These include improving process quality, speeding up the treatment process offered by dental institutes and organizations, increased globalization, rising urbanization, constant need for streamlining dental procedures as well as managing workflows in hospitals, increased investment in oral healthcare and rise in geriatric population. On the contrary, factors that may restrict the dental software market growth includes the complexity of the software that is not accessible by all coupled with the high price of the software which cannot be afforded by all dental clinics and all dentists.

Dental Software Market Share Analysis

Leading players profiled in the dental software market include Patterson Dental, Medicloud, Consult-Pro, Sirona Dental Systems, Inc, Planmeca Oy, Open Dental Software Inc, Imageworks Corporation, Henry Schein, Inc, Gendex Dental System, Dexis, llc, Datacon Dental Systems, Ace Dental Software, Carestream Health, Inc, Dentimax llc., Abeldent Inc and others.

Market Segmentation

Market Research Future report offers an all-inclusive segmental analysis of the dental software market on the basis of type, application, deployment and end-user.

Based on type, it is segmented into dental imaging software, patient education software, treatment planning software, patient communication software and practice management software. Of these, practice management software is projected to have a mammoth market share during the predicted years.

Based on application, the dental software market is segmented into administrative and clinical application. Of these, the clinical application will rule the market with more than 91.9% share.

Based on deployment, it is segmented into cloud-based/web-based model and on-premise model. Of these, the web-based is anticipated to have the largest share in the dental software market over the predicted years.

By end-user, the dental software market is segmented into academics and research institutes and hospitals and clinics. Of these, hospitals and clinics will grab the biggest market share.

Browse More Information:- 

Regional Analysis

Based on region, the dental software market covers growth opportunities and latest trends across North America, Asia Pacific and Europe. Of these, North America will garner a key share of about 48.35% in the dental software market. The factors that have propelled the growth of this market in this region include early adoption of latest technologies and advancement in medical technology. APAC is a key market that is anticipated to expand at an incredible 8.8% CAGR during the predicted years. Europe too has a strong share and is anticipated to have a positive growth over the predicted years.

Create your website with
Get started